Comparison Between Irbsartan and Valsartan on Treatment of Mild to Moderate Essential Hypertension

OBJECTIVE: To evaluate the efficacy and safety of irbsartan and valsartan in treating essential hypertension. METHODS: 2 1 6 patients with mild to moderate essential hypertension were enrolled in and divided into 2 groups by randomized, double blind and double simulate, group A(irbsartan) 110 cases and group B (valsartan) 106 cases. Patients were treated with irbsartan 150-300mg.d-1 or valsartan 80-160mg/d respectively,the doses regulation period was 2 weeks. After blindopen, irbsartan group continued to the sib week.ABPM were measured in another 21 patients before and after treatment with irbsartan 150mg.d-1 for 4 weeks, and T/ P ratio was calculated. RESULTS: The blood pressure of patients decreased significantly after 2 or 4 weeks treatment .The total effective rates were 78.2% and 74.5% respectively, there wasnit any difference between two groups. T/P ofirbratan was 53.5%. Blood pressure decreased continously in the open-treatment period from the 4th week to the 8th week.The incidence of adverse reaction was 17. 1% and 13.9% in 2 groups respectively,which were mild and tolerable. CONCLUSION: Irbsartan and valsratan are effective and safe in treating mild to moderate essential hypertention.